Randomized CO2 vs Sham Laser Treatment of Provoked Vestibulodynia
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/17/2018 |
| Start Date: | August 2018 |
| End Date: | November 2019 |
| Contact: | Catherine A Matthews, MD |
| Email: | camatthe@wakehealth.edu |
| Phone: | 336-716-4310 |
Randomized Controlled Trial of Fractional CO2 Laser vs Sham Laser for Women With Provoked Vestibulodynia Who Have Failed Conservative Management
Vulvodynia is a debilitating chronic vulvar pain lasting at least 3 months without a clear
identifiable cause that is challenging to treat effectively. Vulvodynia is a common pain
condition: its prevalence is estimated at 7-8% in women between the ages of 18 and 40.
Vulvodynia that is provoked and localized to the vestibule (provoked vestibulodynia [PVD])
appears to be the most commonly seen in clinical practice. The current treatment approach for
PVD follows a trial-and-error strategy from one intervention to another if symptoms fail to
remit. Treatment options include reducing vulvar irritation (e.g., by stopping the use of
detergents), topical agents (e.g., lidocaine), oral medications, pelvic floor physical
therapy, psychotherapy, locally injectable agents (e.g., botulinum toxin A), and surgery
(vestibulectomy). Despite the number of available treatment options, treatment failure is
common.
Fractional carbon-dioxide (CO2) laser is a technology widely used in dermatology for the
treatment of various skin conditions. It has also been found to be an effective and safe
treatment modality for symptoms of the genitourinary syndrome of menopause. A recent pilot
study explored the use of fractional CO2 laser for the treatment of vestibulodynia in 37
subjects, 67.6% of which reported that their symptoms were "improved" or "very improved"
after 3 fractional CO2 laser sessions. In addition, the subjects reported
statistically-significant decreases in vulvar pain and dyspareunia scores. Though the results
of this pilot study are promising, it was of small sample size and did not control for the
placebo effect. In cases of PVD, the placebo effect has been found to have a significant
impact on self-reported outcomes. Sham procedures, when performed correctly, can be ethically
administered and can significantly reduce study bias.
The primary aim of this study, therefore, is to assess the difference in vulvar pain
intensity scores, at baseline and at 6, 12, 16, and 24 weeks post-randomization, in women
with refractory PVD assigned to fractional CO2 laser vs sham laser. This study will provide
information about the efficacy of this treatment modality in women with a challenging
clinical condition. Hypothesis: Administration of 3 sessions of fractional carbon-dioxide
laser to the vulvar vestibule of women with refractory provoked vestibulodynia will result in
a clinically-significant greater reduction in vulvar pain intensity scores than placebo (sham
laser).
identifiable cause that is challenging to treat effectively. Vulvodynia is a common pain
condition: its prevalence is estimated at 7-8% in women between the ages of 18 and 40.
Vulvodynia that is provoked and localized to the vestibule (provoked vestibulodynia [PVD])
appears to be the most commonly seen in clinical practice. The current treatment approach for
PVD follows a trial-and-error strategy from one intervention to another if symptoms fail to
remit. Treatment options include reducing vulvar irritation (e.g., by stopping the use of
detergents), topical agents (e.g., lidocaine), oral medications, pelvic floor physical
therapy, psychotherapy, locally injectable agents (e.g., botulinum toxin A), and surgery
(vestibulectomy). Despite the number of available treatment options, treatment failure is
common.
Fractional carbon-dioxide (CO2) laser is a technology widely used in dermatology for the
treatment of various skin conditions. It has also been found to be an effective and safe
treatment modality for symptoms of the genitourinary syndrome of menopause. A recent pilot
study explored the use of fractional CO2 laser for the treatment of vestibulodynia in 37
subjects, 67.6% of which reported that their symptoms were "improved" or "very improved"
after 3 fractional CO2 laser sessions. In addition, the subjects reported
statistically-significant decreases in vulvar pain and dyspareunia scores. Though the results
of this pilot study are promising, it was of small sample size and did not control for the
placebo effect. In cases of PVD, the placebo effect has been found to have a significant
impact on self-reported outcomes. Sham procedures, when performed correctly, can be ethically
administered and can significantly reduce study bias.
The primary aim of this study, therefore, is to assess the difference in vulvar pain
intensity scores, at baseline and at 6, 12, 16, and 24 weeks post-randomization, in women
with refractory PVD assigned to fractional CO2 laser vs sham laser. This study will provide
information about the efficacy of this treatment modality in women with a challenging
clinical condition. Hypothesis: Administration of 3 sessions of fractional carbon-dioxide
laser to the vulvar vestibule of women with refractory provoked vestibulodynia will result in
a clinically-significant greater reduction in vulvar pain intensity scores than placebo (sham
laser).
Inclusion Criteria:
- Aged 18 or older
- Meets the 2015 terminology for the diagnosis of PVD, either type 1 (chronic vulvar
pain since first attempts at intercourse and/or other penetrative activities) or type
2 (chronic vulvar pain with intercourse and/or other penetrative activities following
a period of no vulvar pain)
- Vulvar pain is localized to the vestibule and provoked by vaginal intercourse, other
penetrative activities (e.g., tampon insertion, self-stimulation) and/or pressure
exerted on the vestibule (e.g., due to tight-fitting clothing, cycling)
- Vestibular pain is elicited with cotton-swab test during screening medical examination
- Subject did not experience significant symptom improvement with prior therapy
following a minimum of 2 standard-of-care treatments for PVD
Exclusion Criteria:
- Currently receiving any type of treatment for PVD, including topical agents (e.g.,
lidocaine), oral medications (e.g., tricyclic antidepressants, anticonvulsants),
pelvic floor physical therapy, psychotherapy, or locally injectable agents (e.g.,
botulinum toxin A)
- Generalized vulvar pain
- Unprovoked vulvar pain
- History of vestibulectomy
- Any medical, gynecologic, or iatrogenic condition (e.g., vulvar surgery) that could
explain the presence of chronic vulvar pain (e.g., genitourinary syndrome of
menopause, lichen sclerosus, vaginismus, significant pelvic organ prolapse, pudendal
neuralgia)
- Active vulvar and/or vaginal infection that is not due to bacterial vaginosis,
Chlamydia, Trichomonads or Candida (if diagnosed with any of these infections, treat
and re-evaluate after negative test of cure)
- Active urinary tract infection
- Currently pregnant or breastfeeding
- Recent vaginal delivery (within 3 months post-partum)
- Medical or psychiatric condition not under control
- Scoring of 10 or above on the PHQ-9 and/or scoring 1 or above on the question asking
about "thoughts that you would be better off dead, or of hurting yourself in some way"
- History of treatment with fractional CO2 laser to the vulvar vestibule and/or vagina
- History of radiation to vaginal/colorectal tissue, reconstructive pelvic surgery with
"mesh kits", impaired wound healing or keloid formation, and/or thromboembolic
condition
We found this trial at
1
site
Click here to add this to my saved trials
